Avacta Group (AVCT)

 

AVCT Share PerformanceMore

52 week high98.00 26/05/17
52 week low60.00 31/03/17
52 week change -19.50 (-21.91%)
4 week volume1,022,487 23/09/17

Media for (AVCT)

Presenter: Dr. Alastair Smith
01/08/2014
Presenter: Dr. Alastair Smith
07/05/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Private Shareholder Update Event

RNS Number: 9378T Avacta Group PLC 19 October 2017 19 October 2017 Avacta Group plc ("Avacta" or "the Company") Private Shareholder Update Event Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, will be hosting a Private Shareholder event on Wednesday, 15 November 2017 at 2.00 pm until 4.00 pm at finnCap's offices...

Hardman Res.: R&D accelerated to advance assets

RNS Number: 6904T Avacta Group PLC 16 October 2017 Hardman Res.: R&D accelerated to advance assets R&D accelerated to advance assets - Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which domin...

Avacta to present at Shares Spotlight Evening

Avacta Group chief executive Alastair Smith will be presenting at the Shares Spotlight Evening on 19 Oct at the Novotel Ho...

Avacta to Present at Shares Spotlight Evening

RNS Number: 3574T Avacta Group PLC 12 October 2017 12 October 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta to Present at Shares Spotlight Evening in London Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, is pleased to announce that its Chief Executive Officer, Alastair Smith, wil...

Avacta to present at the Shares Spotlight Evening in London on 19 October 2017

Looking for new investment ideas and want to meet senior directors of listed UK companies? Come along and join Shares ...

Avacta CTO to present at US conference

Avacta chief technology officer, Dr Matt Johnson is presenting at the Annual Biomarkers & Precision Medicine Congress ...

Avacta to Present at Major US Conference

RNS Number: 1238T Avacta Group PLC 10 October 2017 10 October 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta to Present Customer Data at Major US Conference Avacta's Chief Technology Officer will showcase a range of new applications including data generated in collaboration with Covance Avacta Group plc (AIM: AVCT), the ...

Director Dealing and Issue of Equity

RNS Number: 1108T Avacta Group PLC 09 October 2017 09 October 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Director Dealing and Issue of Equity Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that application has been made for 5,311 new ordinary shares of 10p each (the "New...

Fundamental DataMore

EPS-6.86
Dividend yield0 %

Latest discussion posts More

  • AS 091017

    elevator pitch today http://www.youtube.com/watch?v=yuLOFF54y_0 run by proactive investors apparently - never heard of it ...
    9-Oct-2017
    mol42
  • Re: AS 041017

    Yorkshire Post this afternoon http://www.yorkshirepost.co.uk/news/avacta-is-excited-about-future-progress-1-8787759 mol
    4-Oct-2017
    mol42
  • AS 041017

    Interview http://www.proactiveinvestors.co.uk/companies/stocktube/8186/avacta-boss-alastair-smith-anticipating-2018-to-be-a-very-significant-year-8186.html http://www.pro ...
    4-Oct-2017
    mol42

Users' HoldingsMore

Users who hold Avacta Group also hold..
LLOYDS GRP.19%
ROCKHOPPER16%
VODAFONE GRP.12%
BARCLAYS12%
ROYAL BANK SCOT12%

Codes & Symbols

ISINGB00BYYW9G87
SymbolsAVCT, LSE:AVCT, AVCT.L, AVCT:LN, LON:AVCT, XLON:AVCT